Explore the ethical considerations raised in Bottle of Lies regarding the manufacturing practices of generic drugs. How is the dilemma between cost efficiency and ensuring the safety and efficacy of medications presented? What solutions, if any, may be possible for resolving this dilemma?

Analyze the global implications of the issues raised in the book. How do substandard drugs affect public health, particularly in developing countries? What are the responsibilities of pharmaceutical companies in this context?

Some critics, such as Jeremy A. Greene in The Washington Post, have argued that Eban ignores or downplays the instances of corporate malpractice within the American and European brand-name pharmaceutical industries. Research one of these instances and compare it to the depiction of Ranbaxy’s practices. How are the cases different or similar?